Dopamine: A role in the pathogenesis and treatment of hypertension

Journal of Human Hypertension

Volumn 14, Issue , 2000, Pages S47-S50

  Murphy, Michael ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Blood pressure; Dopamine; Hypertension

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; A 32390; ADRENALIN; ALPHA ADRENERGIC RECEPTOR; AMINE; BETA ADRENERGIC RECEPTOR; BRL 8242; CYCLIC AMP DEPENDENT PROTEIN KINASE; DIACYLGLYCEROL; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE BETA MONOOXYGENASE; DOPAMINE RECEPTOR; ENZYME PRECURSOR; EPININE; FENOLDOPAM; FUSARIC ACID; GAMMA GLUTAMYLDOPA; IBOPAMINE; INOSITOL PHOSPHATE; LEVODOPA; NORADRENALIN; PHOSPHOLIPASE C; PRODRUG; SODIUM; UNCLASSIFIED DRUG;

BLOOD PRESSURE REGULATION; CONFERENCE PAPER; DIURESIS; DOSE RESPONSE; DRUG ACTIVATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; HEART RATE; HUMAN; HYPERTENSION; NATRIURESIS; NAUSEA; NORADRENALIN RELEASE; SODIUM EXCRETION; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE; VASODILATATION; VENOUS STASIS;

ANIMALS; BLOOD PRESSURE; DOPAMINE; DOPAMINE AGONISTS; HUMANS; HYPERTENSION; KIDNEY; RECEPTORS, DOPAMINE; SIGNAL TRANSDUCTION; VASODILATION;

EID: 0034130130     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000987     Document Type: Article

References (20)

1. Barger G, Dale HH. Chemical structure and sympathomimetic effects of amines. J Physiol 1910; 41: 19-24.
2. Mannich C, Jacobsohn W. Uber Oxyphenyl-alkylamine und Dioxyphenyl-alkamine. Deutschen Gesellschaft 1910; 43: 189-193.
3. Holtz P, Credner K. Die enzymatische Entstehung von Oxytyramin im Organismus und die physiologische Bedeutung der Dopadecarboxylase. Arch Pharmacol Exp Pathol 1942; 200: 356-388.
4. Goldberg LI, Sjoerdsma A. Effects of several monoamine oxidase inhibitors on the cardiovascular actions of naturally occurring amines in the dog. J Pharmacol Exp Ther 1959; 127: 212-218.
5. Goldberg LI. The pharmacological basis of the clinical use of dopamine. Proc R Soc Med 1977; 70: 7-15.
6. McNay JL et al. Hypotensive effects of dopamine in dogs and hypertensive patients after phenoxybenzam-ine. J Clin Invest 1966; 45: 1045 (abstract).
7. Goldberg LI, Kohli JD, Glock D. In: Woodruff GN, Poat JA, Roberts PJ (eds). Dopaminergic Systems and their Regulation. MacMillan, London, 1986, pp 195-212.
8. Kebabian JW, Caine. Multiple receptors for dopamine. Nature 1979; 277: 93-96.
9. Sibley DR, Monsma FJ. Molecular biology of dopamine receptors. Trends Pharmacol Sci 1992; 13: 61-69.
10. Hussain T, Lokhandwala MF. Renal dopamine receptor function in hypertension. Hypertension 1998; 32: 187-197.
11. Albrecht FE et al. Role of the DlA dopamine receptor in the pathogenesis of hypertension. J Clin Invest 1996; 97: 2283-2288.
12. Murphy MB, Bass AS, Goldberg LI. Modulation of the dopaminergic system in cardiovascular therapeutics. In: Palfreyman MG (eds). Enzymes as Targets for Drug Design. Academic Press, New York, 1990, pp 17-30.
13. Velasco M, Gilbert CA, Rutledge CO, MaNay JL. Anti-hypertensive effect of a dopamine beta hydroxylase inhibitor, bupicomide: a comparison with hydralazine. Clin Pharmacol Ther 1975; 18: 145-153.
14. Hahn RA, Wardell JR, Sarau HM, Ridley PT. Characterisation of the peripheral and central effects of SK&F 52623, a novel dopamine receptor agonist. J Pharmacol Exp Ther 1982; 223: 305-311.
15. Weber RR et al. Pharmacokinetic and pharmacodynamic properties of intravenous fenoldopam, a dopami-nel receptor agonist, in hypertensive patients. Br J Clin Pharmacol 1988; 25: 17-21.
16. Murphy MB et al. Augmentation of renal blood flow and sodium excretion in hypertensive patients during blood pressure reduction by intravenous administration of the dopaminel agonist fenoldopam. Circulation 1987; 76: 1312-1317.
17. Gretler DD et al. Electrocardiographic changes during acute treatment of hypertensive emergencies with sodium nitroprusside or fenoldopam. Arch Intern Med 1992; 152: 2445-2448.
18. Elliott WJ et al. Renal and cardiovascular effects of intravenous fenoldopam or nitroprusside in severe hypertension. Circulation 1990; 81: 970-977.
19. Aronson S et al. Preservation of renal blood flow during controlled hypotension with fenoldopam. Clin Res 1987; 35: 881A.
20. Karnezis TA, Murphy MB, Weber RR. Effects of selective dopamine-1 receptor activation on intraocular pressure in man. Exp Eye Res 1988; 47: 689-697.